Alligator Bioscience: Breakthrough KRAS data reshapes PDAC landscape - Redeye

Revolution Medicines yesterday reported Phase 3 data for daraxonrasib, showing a near doubling of overall survival in patients with pancreatic cancer (PDAC). The results are widely viewed as practice-changing and position KRAS inhibition as a new backbone in PDAC. We comment on the consequences for Alligator.

Länk till analysen i sin helhet: https://www.redeye.se/research/1159596/alligator-bioscience-breakthrough-kras-data-reshapes-pdac-landscape?utm_source=finwire&utm_medium=RSS